Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + epirubicin + mitomycin C
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of 5-fluorouracil, epirubicin, and mitomycin C used primarily for the treatment of advanced gastric cancer. The standard dosing includes 5-fluorouracil 600 mg/m² IV on days 1, 8, 29, and 36; epirubicin 45 mg/m² IV on days 1 and 29; and mitomycin C 10 mg/m² IV on day 1, with cycles repeated every 8 weeks.
02
Targets
TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + epirubicin + mitomycin C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + epirubicin + mitomycin C.